Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial

By sjmartinez • June 4, 2024

Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. J Crohns Colitis. 2024 Jun 3;18(6):885-894. doi: 10.1093/ecco-jcc/jjae007. PMID: 38245818; PMCID: PMC11147797.

Tags: Cedars Sinai DoM, Digestive Diseases, endoscopic improvement–histologic remission, Etrasimod, mucosal healing, Publications, S1P receptor modulator, ulcerative colitis

Short-interval coronary plaque remodeling assessed by serial AI-quantified coronary CTA during intensive plaque-directed therapy

Karlsberg RP, Thummala AR, Elisarraras FX, Golub IS, Cho GW. Short-interval coronary plaque remodeling assessed by serial AI-quantified coronary CTA during intensive plaque-directed therapy. J[...]

A National Institute on Aging workshop on sex differences in health across the lifespan

Pea J, Addie S, Ambrosio F, Anderson RM, Bairey Merz CN, Barr E, Carrington-Lawrence S, de Cabo R, Desvigne-Nickens P, Dubal DB, Haakenson C, Hargove-Grimes[...]

Association between adverse pregnancy outcomes and awareness of cardiovascular risk factors: A nuMoM2b-HHS secondary analysis

Wendl EM, Allshouse AA, Goodwin A, Hobbs B, Greenland P, Levine L, Grobman W, Saade GR, Cameron N, Merz CNB, Rouse C, Rogan S, Chung[...]